Please ensure Javascript is enabled for purposes of website accessibility

Why Rent-A-Center, Achillion Pharmaceuticals, and BP Prudhoe Bay Slumped Today

By Dan Caplinger - Dec 18, 2018 at 4:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Some stocks missed out on the day's minor rally.

Tuesday provided a bit of respite for hard-hit investors, but not everyone was satisfied with the response from the stock market after so many days of downward pressure. Gains on key indexes were generally limited to less than 0.5% as investors seemed reluctant to commit to more bullish views until finding out what the Federal Open Market Committee decides about interest rates. With the central bank's monetary policy group set to conclude its meeting tomorrow, market participants won't have to wait long, but some individual companies suffered setbacks that sent their stocks sharply lower. Rent-A-Center (RCII -0.65%)Achillion Pharmaceuticals (ACHN), and BP Prudhoe Bay (BPT -0.05%) were among the worst performers on the day. Here's why they did so poorly.

No deal for Rent-A-Center

Shares of Rent-A-Center finished lower by 10% after the rent-to-own retail specialist announced that it had terminated a planned acquisition deal from a private equity company. Vintage Capital Management had agreed to pay $800 million for Rent-A-Center six months ago, which would have paid Rent-A-Center investors $15 per share for their stock. Vintage disputes the decision, calling it invalid, but Rent-A-Center believes that it's within its rights to choose not to extend the initial end dates by which the deal had to be done. With antitrust concerns, it's unclear whether the deal would be allowed in any event.

Two people sitting on couch watching a TV with the Rent-A-Center logo on it.

Image source: Rent-A-Center.

Achillion keeps falling

Achillion Pharmaceuticals saw its stock drop for a second straight day, plunging 19%. Some investors had hoped that yesterday afternoon's report of interim data from its phase 2 trial of its oral factor D inhibitor ACH-4471 would help the stock recover from its 23% drop on Monday. Yet after opening higher, Achillion shares resumed their descent, signaling larger problems for the drugmaker. It's apparent that investors wanted more clearly successful findings, and they seem to be growing impatient with the pace of Achillion's development of its drug pipeline.

BP Prudhoe Bay sinks on crude worries

Finally, BP Prudhoe Bay shares finished lower by 17%. The royalty trust is a popular vehicle for investors looking for direct exposure to the oil market, and today's decline of more than 7% sent domestic crude prices close to $46 per barrel. That's the lowest level in more than a year, and it signals concern about whether economic growth will spur demand for energy products amid a glut of supply. Despite impressive dividend yields, BP Prudhoe Bay is fully exposed to falling prices, and too large a drop could threaten the economic viability of the Alaska-based fields -- a potentially catastrophic result for royalty trust investors. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Achillion Pharmaceuticals, Inc. Stock Quote
Achillion Pharmaceuticals, Inc.
ACHN
BP Prudhoe Bay Royalty Trust Stock Quote
BP Prudhoe Bay Royalty Trust
BPT
$19.47 (-0.05%) $0.01
Rent-A-Center, Inc. Stock Quote
Rent-A-Center, Inc.
RCII
$27.53 (-0.65%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.